These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24845945)

  • 21. Mechanistic Model-Informed Proarrhythmic Risk Assessment of Drugs: Review of the "CiPA" Initiative and Design of a Prospective Clinical Validation Study.
    Vicente J; Zusterzeel R; Johannesen L; Mason J; Sager P; Patel V; Matta MK; Li Z; Liu J; Garnett C; Stockbridge N; Zineh I; Strauss DG
    Clin Pharmacol Ther; 2018 Jan; 103(1):54-66. PubMed ID: 28986934
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium.
    Sager PT; Gintant G; Turner JR; Pettit S; Stockbridge N
    Am Heart J; 2014 Mar; 167(3):292-300. PubMed ID: 24576511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative Systems Pharmacology Models for a New International Cardiac Safety Regulatory Paradigm: An Overview of the Comprehensive In Vitro Proarrhythmia Assay In Silico Modeling Approach.
    Li Z; Garnett C; Strauss DG
    CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):371-379. PubMed ID: 31044559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Introduction to
    Park JS; Jeon JY; Yang JH; Kim MG
    Transl Clin Pharmacol; 2019 Mar; 27(1):12-18. PubMed ID: 32055576
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis.
    Cavero I; Crumb W
    Expert Opin Drug Saf; 2005 May; 4(3):509-30. PubMed ID: 15934857
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias.
    Blinova K; Stohlman J; Vicente J; Chan D; Johannesen L; Hortigon-Vinagre MP; Zamora V; Smith G; Crumb WJ; Pang L; Lyn-Cook B; Ross J; Brock M; Chvatal S; Millard D; Galeotti L; Stockbridge N; Strauss DG
    Toxicol Sci; 2017 Jan; 155(1):234-247. PubMed ID: 27701120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A 2015 focus on preventing drug-induced arrhythmias.
    Bossu A; van der Heyden MA; de Boer TP; Vos MA
    Expert Rev Cardiovasc Ther; 2016; 14(2):245-53. PubMed ID: 26560188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A general procedure to select calibration drugs for lab-specific validation and calibration of proarrhythmia risk prediction models: An illustrative example using the CiPA model.
    Han X; Samieegohar M; Ridder BJ; Wu WW; Randolph A; Tran P; Sheng J; Stoelzle-Feix S; Brinkwirth N; Rotordam MG; Becker N; Friis S; Rapedius M; Goetze TA; Strassmaier T; Okeyo G; Kramer J; Kuryshev Y; Wu C; Strauss DG; Li Z
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106890. PubMed ID: 32574700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes.
    Pfeiffer ER; Vega R; McDonough PM; Price JH; Whittaker R
    J Pharmacol Toxicol Methods; 2016; 81():263-73. PubMed ID: 27095424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti-seizure medication: Levetiracetam case study.
    Delaunois A; Mathy FX; Cornet M; Gryshkova V; Korlowski C; Bonfitto F; Koch J; Schlit AF; Hebeisen S; Passini E; Rodriguez B; Valentin JP
    Pharmacol Res Perspect; 2023 Feb; 11(1):e01059. PubMed ID: 36748725
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac safety pharmacology: from human ether-a-gogo related gene channel block towards induced pluripotent stem cell based disease models.
    Kraushaar U; Meyer T; Hess D; Gepstein L; Mummery CL; Braam SR; Guenther E
    Expert Opin Drug Saf; 2012 Mar; 11(2):285-98. PubMed ID: 22103746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prospective IQ-CSRC trial: A prototype early clinical proarrhythmia assessment investigation for replacing the ICH E14 thorough QTc (TQT) study.
    Cavero I; Holzgrefe H; Clements M
    J Pharmacol Toxicol Methods; 2016; 80():1-8. PubMed ID: 26903171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of torsadogenic risk assessment using human induced pluripotent stem cell-derived cardiomyocytes: Japan iPS Cardiac Safety Assessment (JiCSA) update.
    Kanda Y; Yamazaki D; Osada T; Yoshinaga T; Sawada K
    J Pharmacol Sci; 2018 Dec; 138(4):233-239. PubMed ID: 30415824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Uncertainty Quantification Reveals the Importance of Data Variability and Experimental Design Considerations for
    Chang KC; Dutta S; Mirams GR; Beattie KA; Sheng J; Tran PN; Wu M; Wu WW; Colatsky T; Strauss DG; Li Z
    Front Physiol; 2017; 8():917. PubMed ID: 29209226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occurrence of early afterdepolarization under healthy or hypertrophic cardiomyopathy conditions in the human ventricular endocardial myocyte: In silico study using 109 torsadogenic or non-torsadogenic compounds.
    Christophe B
    Toxicol Appl Pharmacol; 2022 Mar; 438():115914. PubMed ID: 35150662
    [TBL] [Abstract][Full Text] [Related]  

  • 38. General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy.
    Li Z; Mirams GR; Yoshinaga T; Ridder BJ; Han X; Chen JE; Stockbridge NL; Wisialowski TA; Damiano B; Severi S; Morissette P; Kowey PR; Holbrook M; Smith G; Rasmusson RL; Liu M; Song Z; Qu Z; Leishman DJ; Steidl-Nichols J; Rodriguez B; Bueno-Orovio A; Zhou X; Passini E; Edwards AG; Morotti S; Ni H; Grandi E; Clancy CE; Vandenberg J; Hill A; Nakamura M; Singer T; Polonchuk L; Greiter-Wilke A; Wang K; Nave S; Fullerton A; Sobie EA; Paci M; Musuamba Tshinanu F; Strauss DG
    Clin Pharmacol Ther; 2020 Jan; 107(1):102-111. PubMed ID: 31709525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CSAHi study-2: Validation of multi-electrode array systems (MEA60/2100) for prediction of drug-induced proarrhythmia using human iPS cell-derived cardiomyocytes: Assessment of reference compounds and comparison with non-clinical studies and clinical information.
    Nozaki Y; Honda Y; Watanabe H; Saiki S; Koyabu K; Itoh T; Nagasawa C; Nakamori C; Nakayama C; Iwasaki H; Suzuki S; Tanaka K; Takahashi E; Miyamoto K; Morimura K; Yamanishi A; Endo H; Shinozaki J; Nogawa H; Shinozawa T; Saito F; Kunimatsu T
    Regul Toxicol Pharmacol; 2017 Aug; 88():238-251. PubMed ID: 28634147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing Drug-Induced Long QT and Proarrhythmic Risk Using Human Stem-Cell-Derived Cardiomyocytes in a Ca2+ Imaging Assay: Evaluation of 28 CiPA Compounds at Three Test Sites.
    Lu HR; Zeng H; Kettenhofen R; Guo L; Kopljar I; van Ammel K; Tekle F; Teisman A; Zhai J; Clouse H; Pierson J; Furniss M; Lagrutta A; Sannajust F; Gallacher DJ
    Toxicol Sci; 2019 Aug; 170(2):345-356. PubMed ID: 31020317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.